 GAITHERSBURG, Md., May 16, 2022 GLOBE NEWSWIRE -- Altimmune, Inc. Nasdaq: ALT, a clinical-stage biopharmaceutical company, today announced that members of the Companys management team will participate at the following investor conferences in May 2022: 